Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;17(4):697-708.
doi: 10.1016/j.hfc.2021.05.013.

Treatment of Advanced Heart Failure-Focus on Transplantation and Durable Mechanical Circulatory Support: What Does the Future Hold?

Federica Guidetti  1 , Mattia Arrigo  2 , Michelle Frank  3 , Fran Mikulicic  3 , Mateusz Sokolski  4 , Raed Aser  5 , Markus J Wilhelm  5 , Andreas J Flammer  3 , Frank Ruschitzka  3 , Stephan Winnik  3
Affiliations
Review

Treatment of Advanced Heart Failure-Focus on Transplantation and Durable Mechanical Circulatory Support: What Does the Future Hold?

Federica Guidetti et al. Heart Fail Clin. 2021 Oct.

Abstract

Heart transplantation (HTx) is the treatment of choice in patients with late-stage advanced heart failure (Advanced HF). Survival rates 1, 5, and 10 years after transplantation are 87%, 77%, and 57%, respectively, and the average life expectancy is 9.16 years. However, because of the donor organ shortage, waiting times often exceed life expectancy, resulting in a waiting list mortality of around 20%. This review aims to provide an overview of current standard, recent advances, and future developments in the treatment of Advanced HF with a focus on long-term mechanical circulatory support and HTx.

Keywords: Advanced heart failure; DCD donors; Heart transplantation; Hemocompatibility; Mechanical circulatory support; RVAD; TAH; Xenotransplantation.

PubMed Disclaimer

Conflict of interest statement

Disclosure A.J. Flammer: fees from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius, Imedos Systems, Medtronic, MSD, Mundipharma, Novartis, Pierre Fabre, Pfizer, Roche, Schwabe Pharma. Vifor, and Zoll, as well as grant support by Novartis, AstraZeneca, and Berlin Heart unrelated to this article. S. Winnik: educational grant support and/or travel support and/or consulting/speaker fees from Abbott, Bayer, Boehringer-Ingelheim, Boston-Scientific, Cardinal Health, Daichi-Sankyo, Fehling Instruments, and Servier. F. Ruschitzka: related to the present work: none. Outside the submitted work: the Department of Cardiology (University Hospital of Zurich/University of Zurich) reports research, educational, and/or travel grants from Abbott, Amgen, AstraZeneca, Bayer, B. Braun, Biosense Webster, Biosensors Europe AG, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, Cardinal Health Switzerland, Daiichi, Diatools, AG, Edwards Lifesciences, Guidant Europe NV (BS), Hamilton Health Sciences, Kaneka Corporation, Labormedizi-nisches Zentrum, Medtronic, MSD, Mundipharma Medical Company, Novartis, Novo Nordisk, Orion, Pfizer, Quin-tiles Switzerland Sarl, Sanofi, Sarstedt AG, Servier, SIS Medical, SSS International Clinical Research, Terumo Deutschland, V-Wave, Vascular Medical, Vifor, Wissens Plus, and ZOLL. F. Ruschitzka has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years (remuneration for the time spent in activities, such as participation in steering committee member of clinical trials, were made directly to the University of Zurich). F. Ruschitzka is an unpaid member of the Pfizer Research Award selection committee in Switzerland. The research and educational grants do not impact on F. Ruschitzka’s personal remuneration. M.J. Wilhelm: travel fees and speaker honoraria from Berlin Heart.